Every material Form 8-K FEMASYS INC has filed with the SEC since August 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Femasys reported that director Kenneth Eichenbaum resigned effective October 30, 2026, after Pointillist ended its right to nominate a board member, and that John Moorhead was appointed to the board the same day as a designee of Nantahala Capital Management, the Lead Investor. The filing says Dr. Eichenbaum's resignation was not due to any dispute with the company, and Mr. Moorhead will serve on the Audit and Compensation Committees.
Kenneth D. Eichenbaum resigned as a director effective October 30, 2026, tied to Pointillist Global Macro Series ending its nomination right under the November 3, 2025 Securities Purchase Agreement
John Moorhead appointed director October 30, 2026 as a designee under an August 7, 2026 side letter with Nantahala Capital Management; he holds a Class II seat expiring at the 2029 annual meeting
Board determined Mr. Moorhead is independent under Nasdaq rules and will serve on the Audit and Compensation Committees
Company issued a press release on October 30, 2026 announcing the appointment (Exhibit 99.1)
Femasys reported that quarterly sales fell 18.9% to $331,827 in the quarter ended June 30, 2026, mainly due to lower FemVue sales, while the quarterly net loss narrowed slightly to $4.47 million from $4.59 million. The company had about $1.4 million of cash at June 30, 2026, and completed a $30 million private placement after quarter-end, which it says gives it resources for its commercial and clinical plans and restored Nasdaq listing compliance.
Quarterly sales were $331,827, down $77,441 or 18.9% from $409,268 a year earlier; six-month sales rose 0.8% to $756,716.
Quarterly net loss was $4,469,095, or $(1.33) per share, versus $4,585,922, or $(3.18) per share, a year earlier; six-month net loss was $3,622,995 versus $10,482,761.
Cash and cash equivalents were about $1.4 million at June 30, 2026, with a $30 million private placement completed after the quarter, which could bring up to $90 million if warrants are fully exercised.
The company said it regained compliance with Nasdaq Listing Requirements and appointed John Canning as Chief Operating Officer.
Femasys Inc. closed a private placement on August 10, 2026, expected to bring in approximately $30.0 million in gross proceeds before offering expenses. The deal included common stock priced at $3.20 per share, plus warrants that could dilute existing holders, and gave the lead investor Nantahala Capital Management rights to appoint up to two board designees.
Purchase agreement dated August 7, 2026; closing occurred August 10, 2026, with expected gross proceeds of approximately $30.0 million
Common stock sold at $3.20 per share; 5,013,559 common shares and 4,361,440 pre-funded warrants issued, plus 18,749,998 accompanying warrants
Warrants exercisable at $2.95 per share; Milestone Warrants require U.S. revenue of at least $1,500,000 in a fiscal quarter and a stock price condition
Five company insiders, including the CEO and CFO, bought securities for an aggregate of approximately $134,000; resale registration statement due within 30 days of closing
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every FEMASYS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →